| Identification | Back Directory | [Name]
[1,1'-Biphenyl]-4,4'-dicarboxamide,N4,N4'-bis[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-, hydrochloride (1:2) | [CAS]
5352-53-4 | [Synonyms]
BPH-1358
[1,1'-Biphenyl]-4,4'-dicarboxamide,N4,N4'-bis[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-, hydrochloride (1:2) | [Molecular Formula]
C32H28N6O2.2ClH | [MDL Number]
MFCD32263017 | [MOL File]
5352-53-4.mol | [Molecular Weight]
565.07 |
| Chemical Properties | Back Directory | [Melting point ]
330 °C | [storage temp. ]
-20°C | [solubility ]
DMF: insol,DMSO: 1 mg/ml,Ethanol: insol,PBS (pH 7.2): insol | [form ]
A solid | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
BPH-1358 (NSC50460) is a potent human farnesyl diphosphate synthase (FPPS) and undecaprenyl diphosphate synthase (UPPS) inhibitor with IC50s of 1.8 μM and 110 nM, respectively, and is active against S. aureus in vitro (MIC ~250 ng/mL)[1][2]. | [in vivo]
BPH-1358 is active against S. aureus in vivo (20/20 mice survived in an i.p. infection model with a MRSA strain)[1]. | [References]
[1] Zhu W, et al. Antibacterial drug leads: DNA and enzyme multitargeting. J Med Chem. 2015 Feb 12;58(3):1215-27. DOI:10.1021/jm501449u
[2] Liu YL, et al. Farnesyl diphosphate synthase inhibitors with unique ligand-binding geometries. ACS Med Chem Lett. 2015 Jan 29;6(3):349-54. DOI:10.1021/ml500528x |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|